title: Melatonin down-regulates MDM2 gene expression and enhances p53 acetylation in MCF-7 cells.
abstract: Compelling evidence demonstrated that melatonin increases p53 activity in cancer cells. p53 undergoes acetylation to be stabilized and activated for driving cells destined for apoptosis/growth inhibition. Over-expression of p300 induces p53 acetylation, leading to cell growth arrest by increasing p21 expression. In turn, p53 activation is mainly regulated in the nucleus by MDM2. MDM2 also acts as E3 ubiquitin ligase, promoting the proteasome-dependent p53 degradation. MDM2 entry into the nucleus is finely tuned by two different modulations: the ribosomal protein L11, acts by sequestering MDM2 in the cytosol, whereas the PI3K-AkT-dependent MDM2 phosphorylation is mandatory for MDM2 translocation across the nuclear membrane. In addition, MDM2-dependent targeting of p53 is regulated in a nonlinear fashion by MDM2/MDMX interplay. Melatonin induces both cell growth inhibition and apoptosis in MCF7 breast cancer cells. We previously reported that this effect is associated with reduced MDM2 levels and increased p53 activity. Herein, we demonstrated that melatonin drastically down-regulates MDM2 gene expression and inhibits MDM2 shuttling into the nucleus, given that melatonin increases L11 and inhibits Akt-PI3K-dependent MDM2 phosphorylation. Melatonin induces a 3-fold increase in both MDMX and p300 levels, decreasing simultaneously Sirt1, a specific inhibitor of p300 activity. Consequently, melatonin-treated cells display significantly higher values of both p53 and acetylated p53. Thus, a 15-fold increase in p21 levels was observed in melatonin-treated cancer cells. Our results provide evidence that melatonin enhances p53 acetylation by modulating the MDM2/MDMX/p300 pathway, disclosing new insights for understanding its anticancer effect.
authors.affiliation: Department of Surgery "P. Valdoni", "Sapienza" University of Rome, Rome, Italy.
authors.forename: Sara
authors.initials: S
authors.lastname: Proietti
authors.forename: Alessandra
authors.initials: A
authors.lastname: Cucina
authors.forename: Gabriella
authors.initials: G
authors.lastname: Dobrowolny
authors.forename: Fabrizio
authors.initials: F
authors.lastname: D'Anselmi
authors.forename: Simona
authors.initials: S
authors.lastname: Dinicola
authors.forename: Maria Grazia
authors.initials: MG
authors.lastname: Masiello
authors.forename: Alessia
authors.initials: A
authors.lastname: Pasqualato
authors.forename: Alessandro
authors.initials: A
authors.lastname: Palombo
authors.forename: Veronica
authors.initials: V
authors.lastname: Morini
authors.forename: Russel J
authors.initials: RJ
authors.lastname: Reiter
authors.forename: Mariano
authors.initials: M
authors.lastname: Bizzarri
mesh_terms: D000107:Acetylation / Q000187:drug effects; D017209:Apoptosis / Q000187:drug effects; D003720:Densitometry; D005260:Female; D005455:Fluorescent Antibody Technique; D006801:Humans; D061986:MCF-7 Cells; D008550:Melatonin / Q000494:pharmacology*; D051736:Proto-Oncogene Proteins c-mdm2 / Q000235:genetics / Q000378:metabolism*; D056564:Sirtuin 1 / Q000378:metabolism; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000378:metabolism*
chemical_list: D016159:Tumor Suppressor Protein p53; D051736:Proto-Oncogene Proteins c-mdm2; C447939:SIRT1 protein, human; D056564:Sirtuin 1; D008550:Melatonin
keywords: AkT; MDM2; MDMX; Sirt1; melatonin; p300; p53-acetylation